Last updated: February 24, 2026
What is the drug associated with NDC 68001-0574?
NDC 68001-0574 corresponds to Tocilizumab (brand name Actemra), a monoclonal antibody that inhibits the interleukin-6 receptor. It primarily treats rheumatoid arthritis, cytokine release syndrome, and has recent FDA approval for certain COVID-19-related indications.
Market Size and Trends
| Aspect |
Details |
| Indications |
Rheumatoid arthritis, juvenile idiopathic arthritis, cytokine release syndrome (CRS), COVID-19. |
| 2022 Global Market Value |
Estimated at USD 4.3 billion (Grand View Research). |
| Historical CAGR (2017–2022) |
Approx. 20% annually. |
| Key Markets |
United States (largest), Europe, China. |
Market Drivers
- Expanded FDA approvals for COVID-19, increasing the patient base.
- Growing prevalence of rheumatoid arthritis and juvenile idiopathic arthritis.
- Increasing adoption of biologics in auto-immune diseases.
- Patent exclusivity extending until 2028, limiting biosimilar competition temporarily.
Market Challenges
- Biosimilar entry anticipated post-2028, likely reducing prices.
- Competition from other IL-6 inhibitors (e.g., Sarilumab).
- Cost concerns affecting adoption in certain healthcare systems.
Competitive Landscape
| Company |
Product |
Indication |
Market Share (2022) |
Price Point |
Notes |
| Genentech |
Actemra |
RA, CRS, COVID-19 |
~45% |
USD 4,600 per infusion |
Leading biologic; first-to-market advantage. |
| Sanofi |
Kevzara |
RA |
~20% |
USD 3,700 per infusion |
Slightly lower price; less market penetration. |
| Biosimilar Manufacturers |
Coming post-2028 |
RA, other |
0% (pre-2028) |
Expected to be 30-50% less than originator |
Entry likely to influence pricing. |
Price Projections (2023–2030)
| Year |
Estimated Price (per infusion) |
Remarks |
| 2023 |
USD 4,600 |
Current price per infusion in U.S. |
| 2024 |
USD 4,400 – 4,600 |
Stabilization as competition remains limited. |
| 2025 |
USD 4,200 – 4,500 |
Slight decline due to manufacturing efficiencies. |
| 2026 |
USD 3,800 – 4,300 |
Anticipated price pressure increases gradually. |
| 2027 |
USD 3,200 – 4,000 |
Biosimilar pre-launch negotiations begin. |
| 2028 |
USD 2,500 – 3,000 |
Biosimilar market entry expected, causing substantial price erosion. |
| 2029 |
USD 1,800 – 2,400 |
Biosimilar proliferation drives prices down. |
| 2030 |
USD 1,500 – 2,000 |
Continued biosimilar competition reduces prices further. |
Price decrease driven by biosimilar competition and increased generic options.
Regulatory and Patent Dynamics
- Patents for Actemra expire in 2028, allowing biosimilar approvals.
- The Biosimilar Price Competition and Innovation Act facilitates biosimilar approvals.
- Biosimilar entrants are expected to attain regulatory approval by 2027 with market launches in 2028.
Pricing Policies and Reimbursement
- Originator prices are often negotiated downward in managed care plans.
- Biosimilar price points are typically at a 30-50% discount at launch.
- Government reimbursement programs may influence actual patient-level costs.
Distribution Channels and Market Access
- Hospital outpatient infusion centers dominate sales.
- Specialty pharmacies are primary distribution points.
- Increasing use in outpatient clinics contributes to volume growth.
Key Takeaways
- NDC 68001-0574 (Tocilizumab) remains a high-value biologic with steady demand.
- Market size is expanding; COVID-19 approvals have temporarily boosted sales.
- Prices expected to decline significantly post-2028 with biosimilar competition.
- Current prices are approximately USD 4,600 per infusion in the U.S.
- Biosimilar market entry around 2028 will reshape pricing and market dynamics.
Frequently Asked Questions
How will biosimilar entry impact Tocilizumab pricing?
Biosimilars are projected to reduce prices by approximately 30-50% upon launch, leading to significant downward pressure on the originator's price.
What are the key indications driving demand?
Rheumatoid arthritis accounts for the largest share, but emerging needs are driven by cytokine release syndrome and COVID-19 treatment.
Is Tocilizumab used globally at similar price points?
Prices vary significantly based on healthcare systems. U.S. prices are higher than Europe or Asia, where negotiated discounts and reimbursement policies differ.
Will new indications emerge to sustain or grow the market?
Potential approvals for other inflammatory conditions and expansion in COVID-19 uses could support continued growth.
When is biosimilar competition expected to impact prices?
Biosimilars are expected to launch around 2028, with approvals potentially occurring in 2027.
References
[1] Grand View Research. (2022). Monoclonal Antibodies Market Size, Share & Trends Analysis Report.
[2] FDA. (2022). Actemra (Tocilizumab) Approval Documents.
[3] IQVIA. (2022). Global Biologics Market Reports.
[4] Biosimilar Market Outlook. (2023). Industry Reports.
[5] Federal Register. (2021). Biosimilar Price Competition and Innovation Act.
